galanin-like-peptide and Hemolysis

galanin-like-peptide has been researched along with Hemolysis* in 1 studies

Other Studies

1 other study(ies) available for galanin-like-peptide and Hemolysis

ArticleYear
Alarin but not its alternative-splicing form, GALP (Galanin-like peptide) has antimicrobial activity.
    Biochemical and biophysical research communications, 2013, May-03, Volume: 434, Issue:2

    Alarin is an alternative-splicing form of GALP (galanin-like peptide). It shares only 5 conserved amino acids at the N-terminal region with GALP which is involved in a diverse range of normal brain functions. This study seeks to investigate whether alarin has additional functions due to its differences from GALP. Here, we have shown using a radial diffusion assay that alarin but not GALP inhibited the growth of Escherichia coli (strain ML-35). The conserved N-terminal region, however, remained essential for the antimicrobial activity of alarin as truncated peptides showed reduced killing effect. Moreover, alarin inhibited the growth of E. coli in a similar potency as human cathelicidin LL-37, a well-studied antimicrobial peptide. Electron microscopy further showed that alarin induced bacterial membrane blebbing but unlike LL-37, it did not cause hemolysis of erythrocytes. In addition, alarin is only active against the gram-negative bacteria, E. coli but not the gram-positive bacteria, Staphylococcus aureus. Thus, these data suggest that alarin has potentials as an antimicrobial and should be considered for the development in human therapeutics.

    Topics: Amino Acid Sequence; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cathelicidins; Cell Membrane; Erythrocytes; Escherichia coli; Galanin-Like Peptide; Hemolysis; Horses; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Molecular Sequence Data; Staphylococcus aureus

2013